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a b s t r a c t
Case-control studies are commonly used to evaluate effectiveness of licensed vaccines after deployment
in public health programs. Such studies can provide policy-relevant data on vaccine performance under
‘real world’ conditions, contributing to the evidence base to support and sustain introduction of new vac-
cines. However, case-control studies do not measure the impact of vaccine introduction on disease at a
population level, and are subject to bias and confounding, which may lead to inaccurate results that
can misinform policy decisions. In 2012, a group of experts met to review recent experience with
case-control studies evaluating the effectiveness of several vaccines; here we summarize the recommen-
dations of that group regarding best practices for planning, design and enrollment of cases and controls.
Rigorous planning and preparation should focus on understanding the study context including
healthcare-seeking and vaccination practices. Case-control vaccine effectiveness studies are best carried
out soon after vaccine introduction because high coverage creates strong potential for confounding.
Endpoints specific to the vaccine target are preferable to non-specific clinical syndromes since the pro-
portion of non-specific outcomes preventable through vaccination may vary over time and place, leading
to potentially confusing results. Controls should be representative of the source population from which
cases arise, and are generally recruited from the community or health facilities where cases are enrolled.
Matching of controls to cases for potential confounding factors is commonly used, although should be
reserved for a limited number of key variables believed to be linked to both vaccination and disease.
Case-control vaccine effectiveness studies can provide information useful to guide policy decisions and
vaccine development, however rigorous preparation and design is essential.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Many new vaccines have been introduced into public health
programs over the past decade and others are under development.
Vaccines are generally licensed based on safety and efficacy as
measured in randomized controlled trials. Once vaccines are intro-
duced into public health programs, their performance under ‘‘real
world” conditions also needs assessment [1], including among
populations with subgroups that may have been excluded from
pre-licensure trials (e.g., malnourished or HIV-infected), with more
variable dosing schedules (e.g. age at administration, interval
between doses, number of doses), against outcomes not included
in randomized clinical trials (e.g. strain-specific protection or mor-
tality), and over more extended periods of time.
Furthermore, some vaccines are licensed based on immunologic
correlates of protection [2], and post-licensure evaluations provide
important information about protection against disease endpoints.
After vaccines have been introduced, conducting placebo-
controlled trials is generally not considered ethical [3]. Observa-
tional post-licensure evaluations are important to underpin policy
decisions on vaccine introduction, to optimize the vaccine program
implementation, and to provide evidence for sustaining vaccine
use and investment from governments and donors.
2. Efficacy, effectiveness and impact
‘Efficacy’, ‘effectiveness’ and ‘impact’ are sometimes used inter-
changeably in everyday language, but in the context of vaccine
studies the terms have come to be used with distinctly different
meanings (although not entirely consistently) [4–7]. Their usage
in this document is defined below:
Efficacy is the percentage by which the rate of the target disease
among those who are vaccinated according to the recom-
mended schedule is reduced compared to the rate in similar
unvaccinated persons. This is generally measured in the context
of a placebo-controlled randomized trial as the ‘‘per protocol”
efficacy (i.e. excluding persons who did not receive the
recommended schedule), because the intention is to establish
the biologic performance capacity of the product under optimal
conditions.
Effectiveness measures the same percent reduction in the rate
of disease as efficacy, but in the context of routine, real-world
use of the vaccine. Vaccine effectiveness may be similar to the
efficacy as measured in clinical trials. However, it often differs
in magnitude because in routine use the population vaccinated
includes some who may have a less robust immune response,
and program implementation (e.g. cold-chain maintenance,
dosing schedules) is more variable than in clinical trial settings.
Impact quantifies the reduction in disease at a population level
following introduction of the vaccine [7]. Impact can be
expressed as a percentage decline or as an absolute change in
the rate of disease. It is determined by a combination of vaccine
effectiveness, vaccine coverage in the population, and any herd
effect (i.e. vaccination of part of the population leading to
reduced transmission of the infection in the community, and
thus lowered risk of disease in both vaccinated and unvacci-
nated persons) [8].
Studies of vaccine efficacy, effectiveness, and impact may use
non-disease outcomes such as colonization as endpoints; however
disease endpoints are more commonly used.
3. Observational methods to assess vaccine effectiveness and
impact
Several observational epidemiologic methods are used to assess
the impact of vaccination programs and the effectiveness of vacci-
nes in routine use [4,5,9]. Examination of trends in disease inci-
dence before and after vaccine introduction measures vaccination
program impact. However this approach requires a stable,
unchanged disease surveillance system before and after the intro-
duction of vaccine. Interpretation of such studies can be challeng-
ing because of changes in measured disease incidence or the true
disease incidence unrelated to vaccination. For example, changes
in healthcare seeking behaviors can increase or decrease measured
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disease incidence, concomitant implementation of non-vaccine
interventions can reduce disease risk, and natural temporal varia-
tion in disease incidence unrelated to vaccination can also occur.
Vaccine effectiveness is generally measured through either
cohort or case-control approaches. Cohort studies estimate effec-
tiveness by comparing the incidence of disease among vaccinated
and unvaccinated persons. Cohort studies require large samples,
may be costly, and accurate data on the vaccination status and
potential confounding variables for an entire population are often
not available, especially in resource-poor settings. The cohort
design may not be practical for diseases with low incidence.
Case-control studies assess effectiveness by comparing the odds
of antecedent vaccination among individuals who develop the
target disease (cases) and among a group of individuals without
the disease (controls) who are representative of the population
from which the cases arise [10,11]. Because efforts are focused
on accurately ascertaining disease status and vaccination history
for a relatively small number of cases and controls (compared to
cohort studies), the method can be resource-efficient and particu-
larly useful for diseases or outcomes that are relatively uncommon.
The screening method, in which the vaccination status of cases is
compared to population-level vaccine coverage, is another
approach for assessing vaccine effectiveness [12]; however accu-
rate data on the proportion of the population vaccinated is often
not available in resource-poor settings.
In recent years, case-control studies have been conducted to
evaluate the effectiveness of Haemophilus influenzae (Hib)
[13–24], pneumococcal [25–32], influenza [33], rotavirus
[34–47], and cholera [48–50] vaccines. Despite being widely used
to evaluate vaccine performance, the case-control methodology is
susceptible to bias and confounding [51,52]. Because vaccine
effectiveness estimates often impact policy decisions and donor
support for vaccines their validity is important. In November
2012, a group of experts met to review recent experience with
case-control studies evaluating effectiveness of several vaccines.
We summarize the recommendations from that group regarding
best practices for the preparation and design of such studies, as
well as the enrollment of cases and controls. (Data collection, vac-
cine status ascertainment, analysis and reporting of results are
discussed in a separate paper [insert reference for paired manu-
script].) While discussions of case-control methodology in general
can be found elsewhere [52,53], here we focus on the application
of these methods to evaluate vaccine effectiveness in resource-
constrained settings.
4. Methodological aspects of case-control vaccine effectiveness
studies
4.1. Preparation for case-control vaccine effectiveness studies
Although data collection for case-control vaccine effectiveness
studies begins after vaccine implementation, rigorous study plan-
ning and preparation, focused on understanding the local study
context, should begin well before cases and controls are recruited,
ideally a year or more beforehand. In the preparatory period, it is
important to assess factors that may affect case ascertainment,
such as healthcare-seeking behavior, barriers to care, determinants
of hospitalization and diagnostic capacities. Different potential
sources of control groups should be considered to identify the
group least likely to lead to bias; for example, if cases are identified
from a source population that includes large slum areas and con-
trols are recruited only from more wealthy areas, the controls
may be very different from cases in ways that could bias effective-
ness estimation. Preparation should also include assessing vaccine
coverage, factors associated with non-vaccination, and the ability
to obtain valid, complete data on vaccination status among the
intended study population. Identifying key potential confounders
and the most accurate ways to measure them are also essential
components of study preparation.
Prior studies of the outcome of interest in the local study con-
text may inform case definitions and strategies for recruitment.
For example, a ‘‘vaccine-probe” study in South Africa found that
a widely used case definition for likely bacterial pneumonia, based
on standardized interpretations of pediatric chest radiographs,
underestimated the burden of pneumonia that could be prevented
with the pneumococcal conjugate vaccine [54]; therefore a subse-
quent case-control vaccine effectiveness study used a modified
case definition aimed at better capturing probable pneumococcal
pneumonia cases in that setting [32]. Health care utilization
studies provide important information on where cases might be
identified for a case-control vaccine effectiveness study, as well
as cases that may be missed by health facility-based studies
[55–57]. Vaccine coverage surveys or analysis of immunization
data from Demographic and Health Surveys or Multiple Indicator
Cluster Surveys can offer insight on the completeness and timeli-
ness of routine immunization in the intended study population,
the availability of documented vaccine histories, and factors asso-
ciated with non-vaccination that may be important confounders
for a vaccine effectiveness study [58]. In the context of a Hib vac-
cine study in the Ukraine it was noted that providers considered
underlying immunocompromising conditions to be a contraindica-
tion for receiving the vaccine; thus children at increased risk for
Hib disease were less likely to receive the vaccine, potentially
leading to an overestimation of the actual effectiveness in the full
population [23]. Identifying important factors that influence likeli-
hood of vaccination during the planning phase can help avoid bias
during study implementation.
4.2. Sample size and feasibility
During the preparatory phase, the feasibility of achieving ade-
quate enrollment during the planned study timeline must be
assessed. The desired study size is determined by the expected
effectiveness (with lower effectiveness requiring larger sample
sizes), anticipated vaccine coverage in the study population, and
the number of controls enrolled per case [9]. Study size may be
based on statistical ‘‘power” (i.e. testing the hypothesis that the
vaccine is significantly protective) or precision-based (i.e. targeting
a certain width of confidence interval) [59]. Sample size calcula-
tions should allow for missing data, adjustment for confounding,
and the expected prevalence of incomplete vaccination (e.g. one
or two doses of a three-dose schedule). Once the desired sample
size is determined, an assessment of the ability to enroll that target
number must take into account the potential for declining inci-
dence of disease over time following vaccine rollout, refusals,
age-eligibility for vaccination, and ability to collect vaccination his-
tories. Thus, simple sample size calculations should be considered
as the minimum necessary number needed to assess the primary
outcome, but enrollment beyond that minimum is likely required
for a robust analysis and the ability to address secondary objectives
(e.g. effectiveness in subgroups, effectiveness of incomplete sched-
ule, and strain-specific effectiveness).
Several planned case-control studies of Hib vaccine effective-
ness were not completed because of lower than anticipated enroll-
ment attributable to rapid declines in invasive Hib disease burden
following vaccine introduction (R. Hajjeh, personal communica-
tion, November 16, 2012). Case-control studies may have limited
power if the number of available cases is small, which can occur
following introduction of highly efficacious vaccines, in settings
that achieve rapid, high coverage and significant herd effects.
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4.3. Timing of study and vaccine coverage
Case-control studies are most likely to be useful when the vac-
cine coverage is between 20 and 80% [9]. At either very low or very
high coverage, unvaccinated persons are likely to differ from the
general population in ways that may be associated with increased
or decreased risk of disease, independent of vaccination. These dif-
ferences may be more pronounced where coverage levels are dri-
ven by individual factors (e.g. lack of access to care, mistrust of
medical system) rather than programmatic factors (e.g. vaccine
stock-outs). Results of several rotavirus case-control studies were
difficult to interpret due to high coverage (>90%) soon after vaccine
introduction [43,60]. Settings with high vaccine coverage (e.g.
greater than 85–90%) are not suitable for case-control vaccine
effectiveness studies because of the strong potential for confound-
ing. High coverage also increases sample size requirements
because more observations are required to detect a significant dif-
ference in vaccination between cases and controls. Furthermore,
high coverage can lead to a rapid decline in cases of the disease
of interest if vaccine efficacy is high. Thus, in contexts where the
coverage is expected to increase quickly following vaccine intro-
duction, it may be preferable to conduct a study in a short time
period after introduction rather than a prolonged study with a
slower rate of enrolment.
4.4. Study endpoints
Endpoints for case-control vaccine effectiveness studies range
from highly specific for the vaccine target (e.g. invasive pneumo-
coccal disease caused by a serotype included in the vaccine or rota-
virus diarrhea) to non-specific (e.g. clinical syndromes such as
pneumonia or acute gastroenteritis). Pathogen-specific endpoints
have precise case definitions that are generally not open to inter-
pretation or variability in the field application. Non-specific out-
comes, however, may be of greater interest from a policy
perspective because of the larger associated burden of disease,
albeit the fraction of that disease preventable by the vaccine may
be low. Yet effectiveness estimates from case-control studies of
non-specific outcomes can be confusing or misleading. For exam-
ple, a systematic review of Hib vaccine effectiveness noted that
case-control studies using radiologically confirmed pneumonia
endpoints may have overestimated effectiveness (compared to
clinical trial estimates of efficacy against that same endpoint),
although the reason for the high point estimates is unclear [61].
Protection against a non-specific endpoint depends on the pro-
portion of the endpoint that is attributable to the pathogen targeted
by the vaccine; this may vary over time or seasonally, be higher or
lower in certain sub-groups (e.g. young infants, malnourished chil-
dren) or be affected by outbreaks of other pathogens with overlap-
ping clinical symptoms. Such variability can result in inconsistent
estimates of effectiveness against non-specific endpoints between
studies. For vaccines that lead to herd effect (e.g. Hib or pneumo-
coccal conjugate vaccine), the proportion of a non-specific endpoint
(e.g. pneumonia) attributable to the vaccine-preventable pathogen
decreases among both vaccinated and non-vaccinated populations;
thus as herd effects increase, effectiveness estimates for non-
specific endpoints will decline. The risk for developing non-
specific clinical syndromes such as all-cause pneumonia or diarrhea
may also be strongly affected by individual-level non-vaccine risk
factors (e.g. poverty, maternal education, crowding); such factors
are difficult to measure well and may be associated with vaccina-
tion status. Furthermore, non-specific endpoints require enrolling
larger numbers of participants, since effectiveness against non-
specific endpoints is lower than that against specific endpoints
[10]. Because of variability in the vaccine-preventable portion and
the strong potential for bias, case-control vaccine effectiveness
studies using non-specific endpoints must be interpreted with care,
and are best conducted only when accompanied by analyses of dis-
ease trends over time or by a nested or parallel evaluation of a more
specific endpoint in the same study setting.
4.5. Identification and enrollment of cases
Once the study endpoint is decided, the endpoint case definition
must be clearly defined to avoid variable inclusion of cases during
study implementation. It is not necessary to enroll all individuals
who develop the disease in a given area or time period for a
case-control study [10]. However, studies should report the pro-
portion of eligible cases enrolled, since low enrollment may result
in selection bias. Some vaccine effectiveness studies focus on a
specific subset of cases because the effectiveness of the vaccine
against the outcome is of particular public health interest (e.g. hos-
pitalized or severe cases). The generalizability of the vaccine effec-
tiveness will be limited to the types of cases included, and such
restrictions must be taken into account in the interpretation of
study findings [51]. Whenever possible and culturally acceptable,
cases among children who have died should be included in case-
control vaccine effectiveness studies, since they represent the most
severe spectrum of disease and failing to include them could bias
the effectiveness estimate if their likelihood of vaccination differs
than that of cases who survive.
4.6. Sources of controls
In all case-control studies, controls should be representative
of the source population from which the cases are selected
[51,62–64]. A way of exploring this is to ask ‘‘If this control had
developed the disease of interest, would he or she have been iden-
tified and included in this study as a case?” If the answer is no, then
the control selection method is probably not appropriate. This
question should be asked at the study design phase, when the
source of potential controls is being determined.
4.6.1. Community controls
In many contexts, it is good practice to seek controls in the com-
munity in which the case resides, since those living in the commu-
nity are most reflective of those who would be identified as cases if
they were to fall ill [62]. The community from which the cases are
derived from can be defined in various ways, depending on the
study context and the available options for identifying controls.
Population-based lists, such as birth registries or population-
based databases in which the cases are included, can be used to
randomly select potential controls [65]. For example, in studies
of the pneumococcal conjugate vaccine in the US [17] and Brazil
[66], birth registries were used to select potential controls, and in
a study in Canada, controls were selected from a health insurance
registry that included all residents in a province [27]. Such lists
should be comprehensive and inclusive, since selecting children
from an incomplete list may limit generalizability [62]. The basis
for the list must not be associated with receipt of vaccines (e.g.
immunization registries that include only vaccinated children).
Lists with the appropriate characteristics often do not exist or are
incomplete in many resource-poor settings, obviating this method
for control selection. If such a list is used to identify controls, then
cases not appearing in the list should be excluded.
Alternatively, community controls may be sought geographi-
cally, for example, around a case’s place of residence. Children from
the same geographic area often tend to be comparable with respect
to underlying risk of disease and access to vaccination, and it is
possible to match on, or adjust for, distance to healthcare facilities
if there is concern about differential access to care. Matching by
neighborhood can also help control for a variety of potential
3298 J.R. Verani et al. / Vaccine 35 (2017) 3295–3302
confounding factors that may be difficult to measure, such as
socio-economic status or other barriers to vaccination [65]. Geo-
mapping of the population in an area can provide a sample frame
fromwhich to select geographically-matched controls, as was done
for a Hib vaccine case-control study in Bangladesh [67]. A less
sophisticated, but more commonly employed, strategy is to iden-
tify the household of the case, and then walk in a random direction
(e.g. by spinning a bottle) from that residence, seeking a suitable
control from the nearest neighboring house. This method is based
on the approach developed for vaccine coverage surveys
[15,21,58]. Having standardized procedures for visiting potential
control households is essential for reducing selection bias [62].
Procedures should include the requirement to visit non-
responsive households multiple times and at different times of
day before excluding their residents as potential controls, since
children whose parents are not at home might be more or less
likely to be vaccinated than children whose parents are at home.
Enrolling community controls can be logistically challenging and
resource-intensive, particularly when tight age-matching criteria
are used. Security concerns can also interfere with recruitment of
community controls; investigators of Hib vaccine effectiveness in
Colombia and Pakistan had to alter control recruitment strategies
due to the safety risks associated with seeking neighborhood con-
trols [24,68]. Conducting control recruitment in locations that are
safer or more convenient can induce substantial biases in the vac-
cine effectiveness measure if residence in those areas is associated
with higher likelihood of vaccination.
4.6.2. Hospital or clinic controls
Another common source of controls for case-control vaccine
effectiveness studies are children hospitalized with illnesses other
than the outcome of interest [62]. The specific inclusion criteria for
hospitalized children to serve as controls must be carefully consid-
ered in the design phase of each study since the local conditions
influence the risk of bias. Children who are hospitalized, particu-
larly those with frequent or prolonged hospitalization, may differ
in important ways, including vaccination history, from the general
population; recruiting from among recently admitted children may
avoid overenrolling children with severe prolonged illness as con-
trols. Children hospitalized with vaccine-preventable diseases
should be excluded as controls, as they are probably less likely to
be vaccinated in general, including with the vaccine under study
[51,62]. Where vaccines that protect against the most common
childhood illnesses (e.g. gastroenteritis, pneumonia) are in routine
use, and therefore children hospitalized with these illnesses cannot
serve as controls, it may be challenging to identify enough eligible
hospital controls [31]. In settings where access to health care is
limited or hospitalization is largely restricted to certain subsets
of children (e.g. children with malnutrition), then hospital controls
may have the advantage of being relatively comparable to hospital-
ized cases with regards to access to care [62]. However, results of a
study in such a context are only generalizable to children who
would be hospitalized when ill.
Controls can also be identified in out-patient clinics that cases
would attend if ill [65], an approach used for Hib vaccine effective-
ness studies in Colombia [68] and Ukraine [23]. However, if immu-
nizations are delivered at the clinic, then controls attending the
clinicwould bemore likely to be vaccinated than the general popula-
tion, aswas found in a study of tuberculosis vaccination in Brazil [69].
Thus, if outpatient clinics are to be used as a source of controls, they
should be clinics where immunizations are not routinely provided.
4.6.3. Controls with same clinical syndrome who are ‘test-negative’ for
the pathogen of interest
Another potential source of controls is children who become ill
with the same clinical syndrome as those with the outcome of inter-
est, but whose illness is shown to have an etiologic pathogen not tar-
geted by the vaccine under evaluation [70–72]. Examples of this
approach include: rotavirus-negative gastroenteritis as controls for
cases of rotavirus [36,41,43], influenza-negative respiratory infec-
tion for cases of influenza [71], pneumococcal or non-purulent/
Hib-negative meningitis as controls for Hib meningitis cases
[18,20], and non-vaccine serotype invasive pneumococcal disease
for cases of vaccine-type invasive disease (also known as the ‘indi-
rect cohort’ or ‘Broome’ method) [73–77]. This approach requires
accurate diagnostic testing and sample collection at an appropriate
time to diagnose the pathogen of interest in order to avoid misclas-
sification. Imperfect test sensitivity and specificity leads to an under-
estimation of effectiveness using test-negative controls [78]. Some
tests, such as culture of blood or cerebrospinal fluid, are too insensi-
tive to reliably identify test-negative controls; however when such
tests detect an etiology that is not preventable by vaccines included
in the national schedule (e.g. pneumococcal meningitis for evalua-
tion of Hib vaccine [before introduction of pneumococcal vaccine],
or non-vaccine-type pneumococcal bacteremia for evaluation of
pneumococcal conjugate vaccine), such individuals can serve as con-
trols. The validity of using test-negative controls has been demon-
strated by re-analyses of data from randomized clinical trials of
influenza [70] and rotavirus [79] vaccines that yielded effectiveness
estimates very similar to the efficacy measured by the original trials.
One major advantage of the test-negative approach is a high
degree of comparability between cases and controls, since controls
would have been enrolled as cases if they had the vaccine-
preventable outcome of interest. It also offers logistical and cost
advantages, since cases and controls can be recruited from within
a single surveillance system. Also, since test results are often not
available at the time of recruitment, bias in ascertainment of vacci-
nation through knowledge of case-control status is less likely. A lim-
itation to this method is that it assumes the vaccine being evaluated
has no effect on the incidence of test-negative cases who will serve
as controls. For pneumococcal conjugate vaccines, this assumption
may not be valid, since their widespread use has been associated
with increases in non-vaccine type pneumococcal carriage and dis-
ease incidence [80]. However, modeling work conducted in conjunc-
tion with indirect cohort analyses indicates that while increases in
non-vaccine type disease (and carriage) among vaccinated individu-
als compared with the non-vaccinated can lead to overestimates of
VE, the magnitude of the overestimation is relatively small, particu-
larly if conducted before vaccine coverage is very high [74,76]. For
influenza vaccine, models have similarly shown that even if influ-
enza infection is presumed to provide transient non-specific immu-
nity to all respiratory infections (and thus individuals vaccinated
against influenza, whowould not benefit from this immunity, would
be over-represented among non-influenza respiratory infection
cases) the impact on effectiveness estimates derived from case-
control studies using the test-negative design is minor [72,81].
4.6.4. Multiple control groups
In some case-control vaccine effectiveness studies two or more
types of control group are enrolled [17,19,40,42]. However, when
the estimates of effectiveness differ by the control group used,
the disparate results are difficult to interpret and communicate
[63]. Multiple control groups may be useful for evaluation of study
methods and identifying bias in different groups. In general, how-
ever, it is preferable to understand the study context well, to con-
sider carefully the best control group before conducting the study,
and then to use one source of controls [62].
4.7. Matching
Matching of cases and controls is often used in vaccine effec-
tiveness studies to increase the statistical efficiency of the analysis
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and to attempt to control for unmeasured confounders [64,65,82].
However, overmatching, which occurs when the matching variable
is strongly associated with vaccination but not (or only weakly)
with the illness, results in a loss of statistical power [83]. Matching
also greatly increases the operational complexity of enrolling con-
trols. Matching in case-control vaccine effectiveness studies is
most commonly done at an individual level, where each enrolled
control is matched to a specific case based on certain criteria
(e.g. date of birth or geographic region). An alternative approach
is ‘frequency’ or ‘stratum’ matching, in which the group of controls
is enrolled based on the frequency of certain characteristics among
all cases (e.g. if 20% of cases are from a certain neighborhood, then
controls are enrolled so that 20% are from that same neighborhood)
[10]. Matching, if used, should be reserved for a limited number of
important variables believed to be linked to both vaccination and
disease (i.e. confounding), since unnecessary matching can lead
to reduced efficiency in the analysis and substantially increases
the complexity of study implementation [65,82,84].
4.8. Control to case ratio
The preferred ratio of controls to cases depends upon the rela-
tive ease (and cost) of enrolling cases and controls. The statistically
most efficient approach is equal numbers of cases and controls, if
they are equally easy to enroll. If the number of cases is limited,
increasing the number of controls per case will increase statistical
power, but generally little additional power is gained by enrolling
more than four controls per case [62]. However, for studies using
individual matching in contexts where vaccine coverage is very
high or very low, more than four controls per case should be con-
sidered, since case-control sets in which all cases and controls have
the same vaccination status will not contribute to the estimates of
effectiveness. In contexts where controls are easy to enroll, for
example from a population-based registry [29], then a higher con-
trol to case ratio may be used.
4.9. Timing of control enrollment
For individually matched case-control vaccine effectiveness
studies, controls should be enrolled concurrently (i.e. for each inci-
dent case enrolled, one or more new matched controls are enrolled
from the population at-risk). Rapid enrollment of matched controls
can reduce recall bias, minimize difficulty obtaining compatible
vaccination histories for cases and controls, and help ensure com-
parability between cases and controls with respect to unmeasured
temporal factors that may affect the risk of developing the out-
come of interest (e.g. outbreaks of viral respiratory infections
increasing the risk for pneumococcal pneumonia). However, rapid
enrollment of matched controls is not always feasible and risks
regarding vaccine history can be mitigated if there is written doc-
umentation, with dates of administration, of vaccination status so
that only doses received before the corresponding case became ill
are considered.
5. Conclusions
Evidence of the protection afforded by new vaccines in the con-
text of real-world immunization programs is important for acceler-
ating and sustaining their uptake globally [85,86]. Case-control
vaccine effectiveness studies, if carefully conducted, can provide
such evidence, complementing data from randomized controlled
trials as well as findings from other observational approaches, such
as analyses of trends in disease incidence over time or cohort stud-
ies. Relative to other observational methods for vaccine evaluation,
case-control studies have some advantages. They do not require a
stable baseline of disease surveillance data prior to vaccine intro-
duction and are often considerably less expensive to perform than
cohort studies. Case-control vaccine effectiveness studies do not
measure the actual impact of vaccine introduction on disease at
a population level. However, when combined with data on pre-
vaccine burden of disease and vaccine coverage, they can be used
to provide insight into the public health impact of vaccines.
The belief that case-control studies are quick and easy to carry
out is misplaced. Case-control vaccine effectiveness studies are
complex and require rigorous planning and implementation. They
are susceptible to various types of bias and, if not conducted rigor-
ously and with careful planning, can produce invalid and poten-
tially misleading results. It is imperative that investigators
understand the study context well to minimize bias and correctly
interpret results. Case-control vaccine effectiveness studies are
most likely to provide reliable information when assessing out-
comes specific to the vaccine being evaluated (e.g. Hib meningitis
rather than all clinical meningitis). Studies using nonspecific out-
comes are particularly challenging and prone to misleading
results; such studies should not be undertaken unless the investi-
gators ensure a high level of rigor and complementary data assess-
ing other more specific outcomes are available from the same or
comparable population. Selection of an appropriate control group
and close attention to potential sources of bias during control
enrollment are crucial. While case-control studies can provide use-
ful information to guide vaccine policy decisions and vaccine
development, they must be thoughtfully planned and rigorously
conducted.
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